med supply
SOLUTIONS

REVOFIL ULTRA
Product Specifications

1-844-226-8277
info@medsupplysolutions.com
medsupplysolutions.com

REVOLUTIONAL PEPTIDES DERMAL FILLER

Elasticity and Fluidity of REVOFIL Fine, Plus, Ultra



Rheological Properties

Viscoelastic properties of REVOFIL

REVOFIL Ultra, Plus, Fine shows high shear storage modulus (G') and stable shear loss modulus (G'') in Dynamic mechanical analysis. The result shows high elasticity, duration and stable fluidity of REVOFIL gels.

Molecular Structure of reticulated HA gel in REVOFIL



in-vitro data

Dermal / Epidermal Cohesive Effect: Increased 81% Collagen 1, 45% Hyaluronic acid





REVOFIL has shown positive regulation of endogenous collagen and hyaluronic acid synthesis in human fibroblast cell.

Direct Inhibition of Hyaluronidase Activity: Decreased 90% Hyaluronidase Activity

Interaction of Hyaluronidase and CG-Boostrin



Inhibition of Hyaluronidase Activity



REVOFIL contains a strong inhibitor of hyaluronidase. CG-Boostrin, a patented peptide, binds to the enzyme strongly and down-regulates the degradation of reticulated hyaluronic acid which implies increased duration of the gel in skin.

Protection of Anti-oxidative stress and Photo-induced Cell Damage

Anti-oxidative Stress Recovery



Photo-induced Cell death Protection



REVOFIL shows strong anti-oxidant effect against oxidative chemical and photo-damage induced UV in human dermal fibroblasts.

Decreased Enzymatic Degradation

Concentration of Hyaluronidase: 25unit/ml
Incubation temperature: 37℃



REVOFIL showed strong resistance to the enzyme which implies longer lasting in skin compared to competitors. The result indicates that the duration of REVOFIL is much longer than other HA Dermal fillers.

in-vivo data

Clinical Test Data Before and After

One hundred seventy-two (172) patients were injected with REVOFIL Fine (30), REVOFIL Plus (86), REVOFIL Ultra (56), aged 20~56. All patients satisfied after injection without allergic effects.
The affirmative results had been reached by 99% in the clinical study. The effectiveness of treatment was expressed in decrease and smoothing of wrinkles in facial area and zone around eyes and increase of volume and improvement in shape of lips, nose and hands.

Soft Touch Filler, REVOFIL Fine

Sex : Male
Age : Early 60's

Product : REVOFIL Fine
Injection Area : Hand Rejuvenation

Sex : Female
Age : Early 40's

Product : REVOFIL Fine
Injection Area : Upper Eyelids

Sub Touch Filler, REVOFIL Plus



Sex : Female
Age : Early 40's

Product : REVOFIL Plus
Injection Area : Nasolabial Folds



Sex : Female
Age : Early 30's

Product : REVOFIL Plus
Injection Area : Lip Augmentation

Deep Touch Filler, REVOFIL Ultra

Sex : Female
Age : Early 30's

Product : REVOFIL Ultra
Injection Area : Fore Head



Sex : Female
Age : Early 50's

Product : REVOFIL Ultra
Injection Area : Nasolabial Folds

Indication and Summary Table

	REVOFIL Fine Soft Touch Filler	REVOFIL Plus Sub Touch Filler	REVOFIL Ultra Deep Touch Filler
Concentration of HA	23 mg/mL	23 mg/mL	23 mg/mL
Needle	30G 1/2	27G 1/2	27G 1/2
Indication	Correction of superficial wrinkles, fine lines, caved scar. Filling of all moderately pronounced wrinkles on the face and tissue.	Filling deep wrinkles and lines. Harmonization of volume and lip contour.	Redefinition of facial contours. Correction of very deep wrinkles in thick skin tissue. Creation of the volume (Cheeks, chin, temporal area)
Injection depth	Superficial dermis 	Mid, Deep dermis	Deep, Subcutaneous dermis
Injection area	Tear Troughs Fine lines, Temporal region Upper Cheeks Cheeks, Hollow Cheek	Fore Head Nose Bridge Nasolabial Folds Marionette lines Tear Troughs Fine lines, Temporal region Upper Cheeks Cheeks, Hollow Cheek Lip Lifting, Augmentation Jaw, Chin, Mandibular region	Fore Head Nose Bridge Nasolabial Folds Marionette lines Cheeks, Hollow Cheek Lip Lifting, Augmentation Jaw, Chin, Mandibular region
Blister pack	1 mL prefilled syringe/pack	1 mL prefilled syringe/pack	1 mL prefilled syringe/pack
Implant Duration Before touch up※	10 months on average	12 months on average	12 months on average

※ Average duration depends on several factors: Patient's skin type, severity of the wrinkles to be corrected, type of injection and the injected volume.



CAREGEN CO., LTD.

1027-22, Hogye-dong, Dongan-gu, Anyang-si,
Gyeonggi-do 431848 South Korea

tel : +82-31-420-9200 **fax** : +82-31-452-3869
e-mail : sales@caregen.com

www.caregen.com / www.renokin.com

med supply
SOLUTIONS

This document is a photographic image of the product insert provided for your convenience by Med Supply Solutions. Med Supply Solutions does not claim ownership of the content contained within this product insert. The intellectual property rights, including but not limited to copyrights, trademarks, and any other applicable rights, pertaining to the content of this product insert, remain the sole property of the original manufacturer. Med Supply Solutions accepts no liability for any inaccuracies, omissions, or discrepancies that may be present in this document. Your use of this product insert is subject to our terms and conditions, which can be found on our website. By accessing and utilizing this document, you acknowledge and accept the terms and conditions outlined therein.

1-844-226-8277
info@medsupplysolutions.com
medsupplysolutions.com